Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 8/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2856411 | 0.83 | ACE (0.46) | PER2TP53POLBITGB3ITGA2B | |
| SCHEMBL2855114 | 0.82 | TSHR (0.44) | PER2TP53HTR2CHTR2B | |
| SCHEMBL5866444 | 0.82 | POLB (0.41) | PER2TP53POLBPLATKMT2A | |
| SCHEMBL2852528 | 0.82 | ITGB3 (0.38) | PER2TP53ITGB3ITGA2B | |
| SCHEMBL5866391 | 0.79 | TP53 (0.41) | PER2TP53HTR2CHTR2B | |
| SCHEMBL2855287 | 0.73 | TP53 (0.37) | PER2TP53HTR2CHTR2B | |
| SCHEMBL5866429 | 0.72 | HPGD (0.51) | PER2TP53POLB | |
| SCHEMBL2865250 | 0.70 | HTR2C (0.39) | TP53HTR2CHTR2BJAK3 | |
| SCHEMBL8417394 | 0.68 | ALDH1A1 (0.32) | POLB | |
| SCHEMBL27689294 | 0.68 | PER2 (0.38) | PER2TP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388195-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-07-12 | — | — | US | disclosed |
| US-20150158882-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2015-06-11 | — | — | US | disclosed |
| US-20030187255-A1 | Therapeutic heterocycles | MILLER SCOTT CARSON (US) | 2003-10-02 | — | — | US | disclosed |
| US-6444809-B1 | ANTIHISTAMINES | ZENECA LIMITED (GB) | 2002-09-03 | — | — | US | disclosed |
| US-6124279-A | NEUROKININ A ANTAGONISTS, ANTIASTHMATIC AGENTS | ZENECA LIMITED (GB) | 2000-09-26 | — | — | US | disclosed |
| US-5990130-A | NOVEL 4-SUBSTITUTED PIPERIDINE DERIVATIVES WHICH ANTAGONIZE NEUROKININ; USEFUL IN TREATMENT OF ASMTHMA AND RELATED CONDITIONS | ZENECA LIMITED (GB) | 1999-11-23 | — | — | US | disclosed |
| US-5567700-A | USEFUL FOR TREATING ASTHMA | ZENECA LIMITED (GB) | 1996-10-22 | — | — | US | disclosed |
| EP-0714392-A1 | HETEROCYCLES USEFUL AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1996-06-05 | — | — | EP | disclosed |
| WO-1995005377-A1 | HETEROCYCLES USEFUL AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1995-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158882-A1 | HETEROCYCLIC COMPOUND | TP53, VHL, MGMT | PER2 3227/4885TP53 1/4885POLB 2206/4885 |
| US-20030187255-A1 | Therapeutic heterocycles | BDKRB2, TK2, TACR2 | PER2 1485/4885TP53 1903/4885POLB 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.